Opportunity Information: Apply for PAR 13 048
Apply for PAR 13 048
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Drug Discovery for Nervous System Disorders (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.273 Alcohol Research Programs 93.279 Drug Abuse and Addiction Research Programs 93.866 Aging Research.
- This funding opportunity was created on Dec 18, 2012 and posted on Dec 18, 2012.
- Applicants must submit their applications by Jan 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Private institutions of higher education Small businesses For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Independent school districts County governments Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) City or township governments Special district governments Native American tribal organizations (other than Federally recognized tribal governments).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH grant opportunity PAR-13-048, titled "Drug Discovery for Nervous System Disorders (R01)," supports research projects focused on finding and testing new therapeutic compounds aimed at preventing or treating disorders of the nervous system. It is set up as an R01 research project grant, meaning it is intended for substantial, hypothesis-driven or milestone-driven research programs that can cover a full preclinical discovery arc, such as identifying promising chemical matter, optimizing it into a stronger lead, and generating the kinds of preclinical evidence needed to justify moving toward clinical development. The central theme is drug discovery and preclinical testing, so applications are expected to go beyond basic biology and move into activities that directly advance a candidate compound or class of compounds toward therapeutic readiness.
This FOA falls under NIH and aligns with several health-related federal assistance areas, including mental health, alcohol research, drug abuse and addiction research, and aging research (CFDA 93.242, 93.273, 93.279, and 93.866). That mix of program codes signals that the announcement is meant to be broad across nervous system disorders, including conditions that intersect with psychiatric disease, substance use disorders, and age-related neurological decline. In practical terms, competitive projects would typically propose a clear target or pathway (or a phenotypic screening strategy), a rational plan for discovering or selecting compounds, and a rigorous preclinical testing approach that demonstrates efficacy signals and addresses common early development risks like selectivity, toxicity, and whether a compound can reach relevant nervous system tissue.
The scope emphasizes "novel compounds," which generally implies that the work should involve new chemical entities, new uses for compounds supported by strong mechanistic rationale, or clearly differentiated lead series rather than incremental tweaks with limited translational value. Because the FOA explicitly highlights discovery and preclinical testing, an applicant would normally be expected to lay out concrete discovery steps such as assay development and validation, screening (target-based or phenotypic), hit-to-lead activities, medicinal chemistry optimization, structure-activity relationship work, and early ADME and safety assessments. For nervous system indications in particular, strong applications would usually consider issues like blood-brain barrier penetration, CNS exposure, behavioral or functional readouts in relevant models, and biomarkers that can translate from animal studies toward eventual human studies.
In terms of who can apply, eligibility is deliberately expansive. Applicants include private and public institutions of higher education, nonprofits (including those with and without 501(c)(3) status), small businesses, and for-profit organizations that are not small businesses, along with a wide range of government entities (state, county, city/township, special district governments, independent school districts, and public or Indian housing authorities). Tribal governments and tribal organizations are included, both federally recognized and other tribal entities, and the opportunity also welcomes applications from mission-focused institution types such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian-serving institutions, and AANAPISI institutions. Importantly, non-U.S. organizations and foreign institutions are eligible to apply, non-U.S. components of U.S. organizations are eligible, and foreign components are allowed as defined by NIH policy, which makes the FOA accessible to international teams where the science and resources are a strong fit.
Administratively, this was a discretionary grant opportunity with no cost sharing or matching requirement, reducing barriers for applicants that might not have non-federal funds available to pair with the award. The announcement was posted and created on December 18, 2012, and it had an original and final closing date of January 7, 2016, with an archive date of February 7, 2016, meaning it is no longer open but remains a useful reference point for the kind of NIH-supported preclinical drug discovery work that was encouraged under this program. The full archived announcement is linked through the NIH grants guide at http://grants.nih.gov/grants/guide/pa-files/PAR-13-048.html, and the contact listed for access or technical linking issues is the NIH Office of Extramural Research webmaster (FBOWebmaster@OD.NIH.GOV).
FAQs: NIH PAR-13-048 - Drug Discovery for Nervous System Disorders (R01)
What is PAR-13-048?
PAR-13-048 is an NIH funding opportunity announcement (FOA) titled "Drug Discovery for Nervous System Disorders (R01)." It supports research projects aimed at discovering and preclinically testing therapeutic compounds intended to prevent or treat disorders of the nervous system.
What type of grant mechanism is this opportunity?
This FOA uses the NIH R01 mechanism (Research Project Grant). It is intended for substantial research programs that are hypothesis-driven or milestone-driven and can support a full preclinical drug discovery arc.
What is the main focus of the funded research?
The central focus is drug discovery and preclinical testing. Applications are expected to move beyond basic biology and include activities that directly advance a candidate compound or a class of compounds toward therapeutic readiness.
What kinds of projects are a strong fit for this FOA?
Projects that propose a clear target or pathway (or a phenotypic screening strategy), a rational plan to discover or select compounds, and a rigorous preclinical testing plan. Competitive projects commonly address early development risks such as selectivity, toxicity, and whether the compound can reach relevant nervous system tissue.
Does the FOA support an end-to-end preclinical discovery program?
Yes. The FOA is described as supporting substantial programs that can cover a full preclinical discovery arc, such as identifying promising chemical matter, optimizing it into a stronger lead, and generating preclinical evidence that could justify movement toward clinical development.
What does "novel compounds" mean in the context of this opportunity?
"Novel compounds" generally implies new chemical entities, new uses for compounds supported by a strong mechanistic rationale, or clearly differentiated lead series rather than incremental tweaks with limited translational value.
What drug discovery activities are expected to be included in an application?
Applications would typically describe concrete discovery and development steps such as assay development and validation, screening (target-based or phenotypic), hit-to-lead work, medicinal chemistry optimization, structure-activity relationship (SAR) studies, and early ADME and safety assessments.
What nervous system-specific considerations are highlighted for strong applications?
For nervous system indications, strong applications would typically consider blood-brain barrier penetration, CNS exposure, behavioral or functional readouts in relevant models, and biomarkers that can translate from animal studies toward eventual human studies.
Which disease or research areas does this FOA align with?
This FOA aligns with multiple health-related federal assistance areas, including mental health, alcohol research, drug abuse and addiction research, and aging research. It is meant to be broad across nervous system disorders, including conditions overlapping psychiatric disease, substance use disorders, and age-related neurological decline.
Which CFDA program areas are associated with this announcement?
The FOA aligns with CFDA areas 93.242, 93.273, 93.279, and 93.866.
Who is eligible to apply?
Eligibility is broad and includes public and private institutions of higher education, nonprofits (with or without 501(c)(3) status), small businesses, for-profit organizations that are not small businesses, and many government entities (state, county, city/township, special district governments, independent school districts, and public or Indian housing authorities).
Are tribal governments and tribal organizations eligible?
Yes. Tribal governments and tribal organizations are included, both federally recognized tribes and other tribal entities.
Are mission-focused institution types specifically welcomed?
Yes. The opportunity welcomes applications from institutions such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian-serving institutions, and AANAPISI institutions.
Can non-U.S. or foreign organizations apply?
Yes. Non-U.S. organizations and foreign institutions are eligible to apply. Non-U.S. components of U.S. organizations are eligible, and foreign components are allowed as defined by NIH policy.
Is cost sharing or matching required?
No. The FOA states there is no cost sharing or matching requirement.
Is this grant opportunity currently open?
No. The announcement is archived and no longer open.
What were the key dates for this FOA?
The FOA was posted and created on December 18, 2012. It had an original and final closing date of January 7, 2016, and an archive date of February 7, 2016.
Where can I find the archived FOA details?
The archived announcement is available through the NIH Grants Guide at http://grants.nih.gov/grants/guide/pa-files/PAR-13-048.html.
Who should be contacted for access or technical linking issues with the FOA page?
The listed contact for access or technical linking issues is the NIH Office of Extramural Research webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Education Health
Next opportunity: Drug Discovery for Nervous System Disorders (R21)
Previous opportunity: BJA FY 13 Adult Drug Court Discretionary Grant Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 048
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 048) also looked into and applied for these:
| Funding Opportunity |
|---|
| Drug Discovery for Nervous System Disorders (R21) Apply for PAR 13 049 Funding Number: PAR 13 049 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Pain in Aging (R01) Apply for PA 13 058 Funding Number: PA 13 058 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Pain in Aging (R21) Apply for PA 13 059 Funding Number: PA 13 059 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Pain in Aging (R03) Apply for PA 13 060 Funding Number: PA 13 060 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Administrative Supplements to NCI Funded Research Projects Funding to Advance Research on Cancers in Women (Admin Supp) Apply for PAR 13 067 Funding Number: PAR 13 067 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20) Apply for PAR 13 068 Funding Number: PAR 13 068 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Dissemination and Implementation Research in Health (R21) Apply for PAR 13 054 Funding Number: PAR 13 054 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Dissemination and Implementation Research in Health (R03) Apply for PAR 13 056 Funding Number: PAR 13 056 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Behavioral Integrative Treatment Development Program (R34) Apply for PA 13 078 Funding Number: PA 13 078 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Behavioral Integrative Treatment Development Program (R01) Apply for PA 13 077 Funding Number: PA 13 077 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Behavioral Integrative Treatment Development Program (R03) Apply for PA 13 079 Funding Number: PA 13 079 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Accelerating the Pace of Drug Abuse Research Using Existing Data (R01) Apply for PAR 13 080 Funding Number: PAR 13 080 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Bridging the Gap Between Cancer Mechanism and Population Science (U01) Apply for PAR 13 081 Funding Number: PAR 13 081 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIDA Research Education Program for Clinical Researchers and Clinicians (R25) Apply for PAR 13 084 Funding Number: PAR 13 084 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U19) Apply for PAR 13 086 Funding Number: PAR 13 086 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (UM1) Apply for PAR 13 087 Funding Number: PAR 13 087 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Planning for a National Center for Particle Beam Radiation Therapy Research (P20) Apply for PAR 13 096 Funding Number: PAR 13 096 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| NCI Experimental Therapeutics Clinical Trials Network with Phase 1 Emphasis (ET CTN) (UM1) Apply for RFA CA 13 006 Funding Number: RFA CA 13 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $850,000 |
| The Influence of the Microbiome on Preterm Labor and Delivery (R01) Apply for RFA NR 13 002 Funding Number: RFA NR 13 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| The Influence of the Microbiome on Preterm Labor and Delivery (R21) Apply for RFA NR 13 003 Funding Number: RFA NR 13 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 048", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.